Pharmacokinetic properties and bioequivalence of gefitinib 250 mg in healthy Korean male subjects

Gefitinib is an anti-cancer drug used to treat non-small cell lung cancer. The objective of this study was to compare the pharmacokinetics and evaluate the bioequivalence of 2 orally administered gefitinib 250 mg tablets in healthy Korean subjects. A randomized, open-label, single-dose, crossover bi...

Descripción completa

Detalles Bibliográficos
Autores principales: Moon, Seol Ju, Kim, Yunjeong, Jeon, Ji-Young, Park, Shin-Jung, Kwak, Yong-Geun, Kim, Min-Gul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Clinical Pharmacology and Therapeutics 2021
Materias:
Bioequivalence Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492391/
https://www.ncbi.nlm.nih.gov/pubmed/34621709
http://dx.doi.org/10.12793/tcp.2021.29.e17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492391/
https://www.ncbi.nlm.nih.gov/pubmed/34621709
http://dx.doi.org/10.12793/tcp.2021.29.e17

Ejemplares similares